Repaglinide |
| Catalog No.GC16036 |
Kir6 (KATP) channel blocker
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 135062-02-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus[1].
Repaglinide reduces postprandial glucose levels by enhancing the early phase of insulin secretion and increasing the total amount of insulin secreted[1].
Repaglinide (AG-EE 623ZW) is very rapidly absorbed (tmax less than 1 hour) with a t1/2 of less than one hour. Furthermore, Repaglinide is inactivated in the liver and more than 90 % excreted via the bile. Repaglinide (1 mg/kg p.o.) is effective (P<0.001) as an insulin-releasing agent in a rat model (low-dose streptozotocin) of type 2 diabetes.
References:
[1]. Wang LC, et al. Characteristics of repaglinide and its mechanism of action on insulin secretion in patients with newly diagnosed type-2 diabetes mellitus.Medicine (Baltimore). 2018 Sep;97(38):e12476.
Average Rating: 5 (Based on Reviews and 8 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *